{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:54:52Z","timestamp":1789671292184,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015226","name":"Shengjing Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007062","name":"Yangzhou University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Materials Today Bio"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.mtbio.2025.102267","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T23:52:02Z","timestamp":1756857122000},"page":"102267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Tumor-homing exosomes enable targeted delivery of siRNA and isoimperatorin for overcoming BTK inhibitor resistance in DLBCL"],"prefix":"10.1016","volume":"35","author":[{"given":"Ruowen","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Ashrafizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8677-8475","authenticated-orcid":false,"given":"Gautam","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuofei","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mtbio.2025.102267_bib1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-Hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.mtbio.2025.102267_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.mtbio.2025.102267_bib3","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.18632\/aging.204006","article-title":"Burden of lymphoma in China, 1990-2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019","volume":"14","author":"Liu","year":"2022","journal-title":"Aging"},{"key":"10.1016\/j.mtbio.2025.102267_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3202","article-title":"Diffuse large B-cell lymphoma","volume":"42","author":"Barraclough","year":"2024","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.mtbio.2025.102267_bib5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/blood.2024024788","article-title":"How I treat older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"145","author":"Wallace","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2025.102267_bib6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41375-023-02120-7","article-title":"Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis","volume":"38","author":"Ren","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.mtbio.2025.102267_bib7","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.mtbio.2025.102267_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216616","article-title":"CD30 protects EBV-positive diffuse large B-cell lymphoma cells against mitochondrial dysfunction through BNIP3-mediated mitophagy","volume":"583","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mtbio.2025.102267_bib9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/13543784.2018.1482273","article-title":"Targeting the B cell receptor pathway in non-Hodgkin lymphoma","volume":"27","author":"Valla","year":"2018","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.mtbio.2025.102267_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ctrv.2018.01.002","article-title":"Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma","volume":"65","author":"Dunleavy","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.mtbio.2025.102267_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.mtbio.2025.102267_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-021-00857-8","article-title":"Bruton tyrosine kinase inhibitors in B-cell malignancies: their use and differential features","volume":"17","author":"Shirley","year":"2022","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.mtbio.2025.102267_bib13","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3390\/molecules28052400","article-title":"Bruton's tyrosine kinase inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials","volume":"28","author":"Rozkiewicz","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.mtbio.2025.102267_bib14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.canlet.2019.07.008","article-title":"Abivertinib, a novel BTK inhibitor: anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia","volume":"461","author":"Huang","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mtbio.2025.102267_bib15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","article-title":"Dermatological toxicities of Bruton's tyrosine kinase inhibitors","volume":"21","author":"Sibaud","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.mtbio.2025.102267_bib16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mtbio.2025.102267_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124545","article-title":"Enhancing siRNA cancer therapy: multifaceted strategies with lipid and polymer-based carrier systems","volume":"663","author":"Dastgerdi","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mtbio.2025.102267_bib18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.canlet.2016.03.045","article-title":"Challenges and opportunities for siRNA-based cancer treatment","volume":"387","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mtbio.2025.102267_bib19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ymthe.2024.01.005","article-title":"The landscape of nanoparticle-based siRNA delivery and therapeutic development","volume":"32","author":"Moazzam","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2025.102267_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107102","article-title":"Nanoparticles and siRNA: a new era in therapeutics?","volume":"201","author":"P\u00e9rez-Carri\u00f3n","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.mtbio.2025.102267_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117296","article-title":"Exosome-based nanoparticles and cancer immunotherapy","volume":"179","author":"Ye","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.mtbio.2025.102267_bib22","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.7150\/thno.52570","article-title":"Engineering exosomes for targeted drug delivery","volume":"11","author":"Liang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.mtbio.2025.102267_bib23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jconrel.2022.05.027","article-title":"Exosomes: large-scale production, isolation, drug loading efficiency, and biodistribution and uptake","volume":"347","author":"Kimiz-Gebologlu","year":"2022","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2025.102267_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216151","article-title":"Exosome-like systems: nanotechnology to overcome challenges for targeted cancer therapies","volume":"561","author":"Garc\u00eda-Fern\u00e1ndez","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mtbio.2025.102267_bib25","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.actbio.2022.01.005","article-title":"Exosome-mediated delivery of transforming growth factor-\u03b2 receptor 1 kinase inhibitors and toll-like receptor 7\/8 agonists for combination therapy of tumors","volume":"141","author":"Lee","year":"2022","journal-title":"Acta Biomater."},{"key":"10.1016\/j.mtbio.2025.102267_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2174\/187152012798764697","article-title":"Natural products: promising resources for cancer drug discovery","volume":"12","author":"Mondal","year":"2012","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.mtbio.2025.102267_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.657826","article-title":"Antiviral activity of isoimperatorin against influenza A virus in vitro and its inhibition of neuraminidase","volume":"12","author":"Lai","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mtbio.2025.102267_bib28","first-page":"275","article-title":"Isoimperatorin inhibits angiogenesis by suppressing VEGFR2 signaling pathway","volume":"39","author":"Xu","year":"2025","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.mtbio.2025.102267_bib29","article-title":"Isoimperatorin alleviates lipopolysaccharide-induced periodontitis by downregulating ERK1\/2 and NF-\u03baB pathways","volume":"18","author":"Fan","year":"2023","journal-title":"Open Life Sci."},{"key":"10.1016\/j.mtbio.2025.102267_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110433","article-title":"Isoimperatorin down-regulates epithelial mesenchymal transition through modulating NF-\u03baB signaling and CXCR4 expression in colorectal and hepatocellular carcinoma cells","volume":"99","author":"Kim","year":"2022","journal-title":"Cell. Signal."},{"key":"10.1016\/j.mtbio.2025.102267_bib31","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3892\/ol.2016.5387","article-title":"Isoimperatorin induces apoptosis of the SGC-7901 human gastric cancer cell line via the mitochondria-mediated pathway","volume":"13","author":"Tong","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.mtbio.2025.102267_bib32","first-page":"7993","article-title":"Effects of isoimperatorin on proliferation and apoptosis of human gastric carcinoma cells","volume":"15","author":"Yang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.mtbio.2025.102267_bib33","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.3390\/ijms25084248","article-title":"Apoptotic effect of isoimpertorin via inhibition of c-Myc and SIRT1 signaling Axis","volume":"25","author":"Ko","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mtbio.2025.102267_bib34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12951-020-00738-8","article-title":"Construction of homologous cancer cell membrane camouflage in a nano-drug delivery system for the treatment of lymphoma","volume":"19","author":"Zhao","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.mtbio.2025.102267_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jconrel.2014.03.054","article-title":"Controlled drug delivery systems: past forward and future back","volume":"190","author":"Park","year":"2014","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2025.102267_bib36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mtbio.2025.102267_bib37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41578-020-00269-6","article-title":"Targeted drug delivery strategies for precision medicines","volume":"6","author":"Manzari","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.mtbio.2025.102267_bib38","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41578-021-00394-w","article-title":"Drug delivery to the central nervous system","volume":"7","author":"Nance","year":"2022","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.mtbio.2025.102267_bib39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: structure, regulation and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.mtbio.2025.102267_bib40","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/ijms22010385","article-title":"Safe nanoparticles: are we there yet?","volume":"22","author":"Najahi-Missaoui","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mtbio.2025.102267_bib41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0169-409X(95)00039-A","article-title":"Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system","volume":"17","author":"Storm","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mtbio.2025.102267_bib42","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1002\/smll.201303540","article-title":"Zwitterionic\u2010coated \u201cstealth\u201d nanoparticles for biomedical applications: recent advances in countering biomolecular corona formation and uptake by the mononuclear phagocyte system","volume":"10","author":"Garc\u00eda","year":"2014","journal-title":"Small"},{"key":"10.1016\/j.mtbio.2025.102267_bib43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10787-022-01115-7","article-title":"Exosome engineering in cell therapy and drug delivery","volume":"31","author":"Sadeghi","year":"2023","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.mtbio.2025.102267_bib44","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","article-title":"Extracellular vesicles as a next-generation drug delivery platform","volume":"16","author":"Herrmann","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2025.102267_bib45","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canlet.2020.05.036","article-title":"Functionalized exosome harboring bioactive molecules for cancer therapy","volume":"489","author":"Kim","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mtbio.2025.102267_bib46","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.7150\/thno.39434","article-title":"Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs","volume":"10","author":"Qiao","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.mtbio.2025.102267_bib47","doi-asserted-by":"crossref","first-page":"9355","DOI":"10.2147\/IJN.S281890","article-title":"Advances in exosome-based drug delivery and tumor targeting: from tissue distribution to intracellular fate","volume":"15","author":"Shao","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.mtbio.2025.102267_bib48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.mtbio.2025.102267_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.biomaterials.2017.01.004","article-title":"Exosome-SIRP\u03b1, a CD47 blockade increases cancer cell phagocytosis","volume":"121","author":"Koh","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2025.102267_bib50","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1158\/1541-7786.MCR-20-0956","article-title":"Exosomal CD47 plays an essential role in immune evasion in ovarian cancer","volume":"19","author":"Shimizu","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.mtbio.2025.102267_bib51","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12951-023-01973-5","article-title":"Extracellular vesicles: a rising star for therapeutics and drug delivery","volume":"21","author":"Du","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.mtbio.2025.102267_bib52","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2022.01.005","article-title":"Tumor cell-derived exosomes deliver TIE2 protein to macrophages to promote angiogenesis in cervical cancer","volume":"529","author":"Du","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mtbio.2025.102267_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2024.114141","article-title":"Cancer cell-derived exosome based dual-targeted drug delivery system for non-small cell lung cancer therapy","volume":"244","author":"Wang","year":"2024","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.mtbio.2025.102267_bib54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/pharmaceutics16010033","article-title":"Synergistic phototherapy-molecular targeted therapy combined with tumor exosome nanoparticles for oral squamous cell carcinoma treatment","volume":"16","author":"Li","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2025.102267_bib55","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1038\/s41467-019-11718-4","article-title":"Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy","volume":"10","author":"Yong","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2025.102267_bib56","first-page":"61","article-title":"Drug loading techniques for exosome-based drug delivery systems","volume":"76","author":"Xi","year":"2021","journal-title":"Pharmazie"},{"key":"10.1016\/j.mtbio.2025.102267_bib57","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/cells12101416","article-title":"Current strategies for exosome cargo loading and targeting delivery","volume":"12","author":"Zeng","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.mtbio.2025.102267_bib58","series-title":"Electroporation. Cold Spring Harbor Protocols 2019","author":"Kumar","year":"2019"},{"key":"10.1016\/j.mtbio.2025.102267_bib59","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12943-024-02057-0","article-title":"Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the \"Smart\" exosome nanoparticle therapy","volume":"23","author":"Wu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.mtbio.2025.102267_bib60","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1158\/1078-0432.CCR-21-2547","article-title":"Safety and efficacy of pembrolizumab in combination with acalabrutinib in advanced head and neck squamous cell carcinoma: phase 2 proof-of-concept study","volume":"28","author":"Taylor","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mtbio.2025.102267_bib61","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1151592","article-title":"A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells","volume":"5","author":"Natarajan","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.mtbio.2025.102267_bib62","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/s41467-024-46220-z","article-title":"Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphoma","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2025.102267_bib63","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1186\/s12885-019-6208-x","article-title":"Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count","volume":"19","author":"Li","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.mtbio.2025.102267_bib64","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3324\/haematol.2014.113472","article-title":"Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial","volume":"100","author":"Riihij\u00e4rvi","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.mtbio.2025.102267_bib65","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.3390\/jcm9082418","article-title":"Inflammatory cells in diffuse large B cell lymphoma","volume":"9","author":"Tamma","year":"2020","journal-title":"J. Clin. Med."}],"updated-by":[{"DOI":"10.1016\/j.mtbio.2026.103005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000}},{"DOI":"10.1016\/j.mtbio.2026.103005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000}}],"container-title":["Materials Today Bio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006425008373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006425008373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T09:33:35Z","timestamp":1766396015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590006425008373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":65,"alternative-id":["S2590006425008373"],"URL":"https:\/\/doi.org\/10.1016\/j.mtbio.2025.102267","relation":{},"ISSN":["2590-0064"],"issn-type":[{"value":"2590-0064","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-homing exosomes enable targeted delivery of siRNA and isoimperatorin for overcoming BTK inhibitor resistance in DLBCL","name":"articletitle","label":"Article Title"},{"value":"Materials Today Bio","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mtbio.2025.102267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102267"}}